SGMT Stock Analysis: Buy, Sell, or Hold?
SGMT - Sagimet Biosciences Inc. Series A Common Stock
$7.74
0.13 (1.71%)
▲
5d:
+9.63%
30d:
+12.83%
90d:
+45.49%
BUY
MODERATE Confidence
Analysis Updated: Jul 6, 2026 12:00 AM ET
Earnings: Aug 12, 2026
Get Alerted When SGMT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: SGMT shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: SGMT shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: SGMT is currently trading at $7.74, which is considered extended relative to its 30-day fair value range of $6.52 to $7.40.
Technical Outlook: Technically, SGMT is in a strong uptrend. The price is approaching resistance at $7.95. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: SGMT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (3th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $26.20 (+238.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SGMT is in a strong uptrend. The price is approaching resistance at $7.95. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: SGMT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (3th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $26.20 (+238.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$6.52 -
$7.40
Company Quality Score
56/100
(HOLD)
Options IV Signal
3th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
70.8%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 3th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 238.5% below Wall St target ($26.20)
Trading Range Analysis
30-Day Trading Range
$6.52 -
$7.40
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$0.95
(12.3%)
Support & Resistance Levels
Support Level
$6.68
Resistance Level
$7.95
Current Trend
Strong Uptrend
Technical data as of
Jul 6, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.90
Wall Street Target
$26.20
(+238.5%)
Share & Embed Analysis
Last updated: July 06, 2026 9:01 PM ET
Data refreshes hourly during market hours. Next update: 10:01 PM
Data refreshes hourly during market hours. Next update: 10:01 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SGMT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
David Happel
SELL
12101 shares
2026-02-10
Thierry Chauche
SELL
1312 shares
2026-02-10
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$435 | 60 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 53 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 62 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 56 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 55 HOLD |
